Inclusion Criteria:

- Subject whom should have the pathologically confirmed for unresectable (impossible to
try Total mesorectal excision) rectal cancer with liver metastasis.

- Over 18 years

- ECOG 0-1

- Proper organ function (hepatic transaminases : < ULN ⅹ5, Bilirubin: < ULNⅹ2,
creatinine (serum): < ULNⅹ 1.5, PLT > 100,000Ul, ANC > 1,500/Ul

- more than one target lesion (standard by RECIST 1.0)

- Who should sign on the Informed consent form before participate the trial.

Exclusion Criteria:

- Metastasis in other organ except liver (No matter whether have resection or not)

- Chronic active hepatitis or cirrhosis

- History of treatment for colorectal cancer

- Subject pregnant or breast feeding

- Uncontrolled disease (eg. infection, hypertension, heart failure, Myocardial
Infarction within 6months)

- Have been used FOLFOX as an adjuvant therapy

- Have had adjuvant therapy within 6months

- Uncontrolled peripheral nerve infection

- Alcoholic or drug addict

- Subject currently is enrolled in or ≤30 days from ending other clinical trial.

- History of other type of cancer except resolved from skin cancer and cervical cancer.